Purpose: Tuberous sclerosis (TSC) is an autosomal dominant inherited disease caused by mutations in the TSC1 or TSC2 gene and results in the over-activation of the mammalian target of the rapamycin (mTOR) signaling pathway. Rapamycin, an mTOR inhibitor, is clinically used to treat hamartomatous lesionsas in TSC and its effect on controlling epilepsy is also reported in many studies. This study aims to evaluate the risk factors of pharmacoresistant epilepsy in patients with TSC receiving long-term rapamycin treatment. Method: A total of 108 patients with TSC taking rapamycin for over 1 year were enrolled in this study. Factors that might influence seizure control were statistically analyzed by multiple factor analysis. A subgroup analysis was also conducted to access the relationship between calcified epileptic foci and pharmacoresistant epilepsy. (Clinical trial registration number: ChiCTR-OOB-15006535(2015-05-29)). Results: Seizure was controlled in 53 patients but was not managed in 55 patients considered to be drug resistant. Logistic regression analysis showed that calcification in the cerebral parenchyma was a risk factor of pharmacoresistant epilepsy [P = 0.006, odds ratio (OR) = 4.831 (1.577, 14.795)]. Fifteen of 17 patients with calcified epileptic foci suffered from pharmacoresistant epilepsy (88.2%). Seizures in patients with calcified epileptic foci were probably pharmacoresistant (P = 0.010). Conclusion: Calcification in epileptic foci strongly indicates pharmacoresistant epilepsy in patients with TSC even when treated with appropriate anti-epilepsy drugs (AEDs) and rapamycin. Calcification can be used to evaluate pharmacoresistant epilepsy in patients with TSC.
Introduction
Tuberous sclerosis (TSC) is an autosomal dominant inherited disease caused by mutations in the TSC1 or TSC2 gene and results in overactivation of the mammalian target of the rapamycin (mTOR) signaling pathway [1] . TSC produces hamartomatous lesions in the brain, kidney, skin, and other organs of the body. Epilepsy is observed in approximately 90% of patients with TSC, and approximately half of the patients have experienced infantile spasms (IS) and the majority are pharmacoresistant [2] . In children with TSC, uncontrolled seizure is associated with high risk of developmental delays and autism spectrum disorders [3] .
New and old anti-epilepsy drugs (AEDs), such as valproic acid, carbamazepine, oxcarbazepine, topiramate, and vigabatrin (VGB), are used to control seizures in TSC; of which, VGB is the most effective [4] . VGB can stop seizures in up to 95% of patients with IS affected by TSC [5] . VGB can also effectively control partial seizures [6] . However, visual-field loss caused by VGB is irreversible, and its risk rises with increasing dosage and treatment duration [7] .
In recent years, mTOR inhibitors, such as rapamycin and everolimus, have been clinically used to treat various manifestations of TSC. They can reduce the volume of sub-ependymal giant-cell astrocytoma (SEGA) and renal angiomyolipoma (AML); improve or stabilize pulmonary function in lympangioleiomyomatosis; and improve skin T lesions [8, 9] . Open-label and double-blinded, placebo-controlled studies reported that everolimus was effective on treating TSC-related epilepsy [10] [11] [12] . A case series [13] and our previous observational study [14] indicated that rapamycin can be administered to effectively decrease seizures. However, pharmacoresistant epilepsy remains a challenge even when mTOR inhibitors are used.
Surgery is an option for patients with TSC and intractable epilepsy. Although tubers are multiple, epileptogenic activity can often be localized to one or two tubers [15] . Many neuroimaging technologies, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET), are clinically used to locate epileptogenic tubers and associated epileptogenic regions. Surgery can stop seizures in 57% of drug-resistant patients [4] , but convergent clinical, video electroencephalographic, MRI, and ancillary testing data are needed to select candidate patients for surgery.
Considering that remission of seizures is associated with high intelligence quotient (IQ) [2] , we retrospectively analyzed risk factors affecting seizure control in patients with TSC taking rapamycin for over 1 year.
Results
The clinical characteristics of the patients are summarized in Table 1 . A total of 108 patients, of which 55 were males, were enrolled in this study. The participants aged 3 months to 10 years old, with an average age of 2.2 years and median age of 1.4 years. Forty six patients had IS, 24 patients had partial seizures, and 38 patients had generalized seizures at enrolled time. Thirteen AEDs, including topiramate, valproic acid, vigabatrin, levetiracetam, and clonazepam, were used to control seizure onset. Two patients (partial seizures) given with rapamycin alone and without traditional AEDs achieved seizure free.
Fifty-three patients (49%) receiving AEDs and rapamycin for more than 1 year were declared seizure free. Logistic regression analysis showed that calcification in the cortex and other cerebral parenchyma was a risk factor of pharmacoresistant epilepsy [P = 0.006, OR = 4.831 (1.577, 14.795)]. Age, gender, genotype, seizure type, and family history were not considered risk factors of pharmacoresistant epilepsy in patients with TSC under long-term use of rapamycin (Table 1) .
Seizure reduction ≥50% was observed in 23 of 75 patients without cerebral parenchyma calcification and in 9 of 33 patients with cortex and other cerebral parenchyma calcification. These patients have pharmacoresistant epilepsy according to the definition of drug-resistant epilepsy (ILAE, 2010) [16] , which is failure of adequate trial of two drug schedules to achieve sustained seizure freedom. A subgroup analysis was conducted in 33 patients with cortex and other cerebral parenchyma calcification. Seventeen patients showed calcification in epileptic foci, and 15 of them (88.2%) were considered pharmacoresistant. Of 16 patients with calcification unrelated to epileptiform discharge site, seven patients (43.8%) manifested pharmacoresistant epilepsy. Hence, seizures in patients with cerebral parenchyma calcification in epileptic discharge site were likely to be pharmacoresistant (P = 0.010). Calcification in the epileptic foci strongly suggested the presence of pharmacoresistant epilepsy in patients with TSC even when treated with appropriately selected AEDs and rapamycin.
Discussion

Rapamycin and TSC
Rapamycin, also known as sirolimus, is a natural product isolated from soil bacteria. Open-label and double-blinded, placebo-controlled studies reported that everolimus, the analog or rapamycin, can effectively treat SEGA, AML, and other neurological and nonneurological manifestations in patients with TSC and epilepsy [8, 9] . These effects of rapamycin were also described [13, 14] . The evidence level of case series and observational study is lower than that of randomized controlled trials (RCT).However, the price of rapamycin is approximately half that of everolimus in China, and none of them was covered by medical insurance. Treatment with rapamycin can save approximately 1000 dollars a month for a child weighing 25 kg (everolimus 5 mg/m 2 / day [11] ). Moreover, sirolimus oral solution is suitable for infants and toddlers. This work, which is part of an observational study using rapamycin for children with TSC, indicated that 53 patients (49%) became seizure free. Seizure reduction ≥ 50% was observed in 32 patients (29.6%), who were also considered to have pharmacoresistant epilepsy in this study. Among patients with TSC and epilepsy, 62.5% developed refractory epilepsy and 33.5% achieved epilepsy remission [3] prior to clinical use of mTOR inhibitors. RCTs on the use of everolimus are usually limited by sample size, and the total number of patients declared to be seizure free has not been calculated yet.
Seizure remission is associated with high IQ [2] ; as such, risk factors of pharmacoresistant epilepsy were retrospectively analyzed in the present study. Logistic regression analysis showed that calcification in the cortex and other cerebral parenchyma was a risk factor of pharmacoresistant epilepsy (P = 0.006, OR = 4.831 [1.577, 14 .795]). Age, gender, genotype, seizure type, and family history were not considered as risk factors of pharmacoresistant epilepsy in patients with TSC under long-term use of rapamycin. However, brain MRI data were not analyzed due to lack of digitized image.
Calcification in cerebral parenchyma
Calcification in cortical tubers occurs in 54% of patients with TSC, and its incidence increases with increasing age [17] . Gallagher et al. [18] reported a progressive calcified tuber in a young male with TSC, suggesting that tubers with calcification components are not necessarily static lesions. In the present study, rapamycin was found to less effective in controlling epilepsy in patients with cerebral cortical calcification.
Inflammation is found in tubers of TSC [19] . A histopathological study of TSC classified tubers into three types: 1) low density of giant cells or dysmorphic neurons; 2) high density of giant cells or dysmorphic neurons, and 3) giant cells, dysmorphic neurons, and calcifications [20] . The levels of pS6 (phosphorylated S6-ribosomal protein), T-cells/mm 2 , Cr3/43, and vessels/mm 2 were high in tubers with calcification. Inflammation might be pronounced in calcified tubers and may be partially responsible for the poor response of the patients to mTOR inhibitors. Subgroup analysis showed that seizures in patients with cerebral parenchyma calcification in epileptic discharge site were likely to be pharmacoresistant (P = 0.010). Calcification in the epileptic foci strongly suggested pharmacoresistant epilepsy in patients with TSC even when treated with appropriate AEDs and rapamycin. Surgery can stop seizures in 57% of patients with TSC and drug-resistant epilepsy and can potentially improve their development and cognitive function [21] . Fig. 1 . A typical case. This is a 3-year-old female patient with drug-resistant epilepsy as a result of TSC. Depigmentation spots was found 1 month after birth and her first seizure (partial seizure) occurred when she was 2 months old, manifesting right obliqued eyes and right eyelid twitching lasting for about 3 min. CT image showed dense in right temporal (a) and video EEG showed right temporal sharp waves (b). A TSC1 mutation was found. Rapamycin was used when she was 3 months old. Depigmentation spots disapeared 3 months after using rapamycin, however, seizure onsets was not controlled even topiramate, levetiracetam,vigabatrin and phenobarbital were used. The alpha-methyl-tryptophan PET scan showed inhomogeneous dense tubers with annular calcification and decreased uptake over the right temporal and parieto-temporo cortex (c).
CT is of value for TSC
MRI can be used to obtain images with excellent contrast among various normal structures and is highly sensitive in detecting pathological lesions. CT presents an absolute advantage in showing calcification. CT is superior to MRI in demonstrating the presence of subependymal nodules and brain calcification, thereby confirming or establishing the diagnosis of TSC [22, 23] . Although CT and MRI have their own advantages in showing TSC lesions, and CT is of value in evaluating pharmacoresistant epilepsy in TSC because it can screen patients with calcification in cerebral parenchyma.
This study present several limitations in terms of sample size and retrospective nature. A large number of cases should be evaluated to determine the effect of calcification in the cortex and other cerebral parenchyma on pharmacoresistant epilepsy in patients with TSC. Furthermore, calcification with CT values and size is not quantifiable in a standardized manner. We plan to perform follow up evaluation of patients with epilepsy who underwent surgery to determine treatment outcomes.
Conclusions
Our study showed that calcification in the epileptic foci strongly suggested pharmacoresistant epilepsy in TSC patients even appropriately selected AEDs and mTOR inhibitor rapamycin were used, and CT was of value on evaluating pharmacoresistant epilepsy in TSC patients.
Methods
Patients
All patients diagnosed with TSC at the Pediatric Center of Chinese PLA General Hospital between 2012 January and 2016 January were enrolled in this study.
Subjects were included if they satisfied the following criteria: (1) clinical findings consistent with a definitive diagnosis of TSC, (2) manifest seizures, (3) informed consent provided by their parents with regard to the use of rapamycin, and (4) regular rapamycin use for over 1 year.
The exclusion criteria were as follows: (1) incomplete clinical data, (2) irregular use of AEDs or rapamycin, and (3) less than 1 year of rapamycin treatment.
Rapamycin was first introduced at 1 mg/m 2 /day with a target plasma concentration of 10 ng/ml. The patients returned to our center 3, 6, and 12 months after the start of rapamycin treatment. Video electroencephalography (EEG), routine blood cell count, blood biochemistry, plasma concentration of rapamycin and other AEDs, and seizure frequency and onset were assessed at each visit. No dietary therapy, vagus nerve stimulator, or immunomodulatory therapy was used in this study.
Data collection
Medical history data, including age, gender, cognitive function, seizure onset, and AEDs, were obtained from the patients during their first visit. Video EEG (international standard 10-20 system), brain MRI, and CT analyses were performed. Before taking rapamycin, routine blood cell count and biochemistry (alanine aminotransferase, aspartate aminotransferase, creatinine, carbamide, lithic acid, total cholesterol, triglyceride, high density lipoprotein, and low density lipoprotein) were analyzed as per clinical practice. Patients without seizure onset for more than 6 months were considered seizure free.
Epileptic foci were judged preliminarily in accordance to the clinical manifestation of epileptic seizures, video EEG data, and imageology examination. A typical case is illustrated in Fig. 1 .
Data analysis
Data were analyzed using SPSS 21.0. Logistic regression was used to assess significant factors, and the 95% confidence interval of odds ratio (OR) was calculated. Chi-square and Fisher's exact probability tests were used for categorical data. Values at P < 0.05 (two-sided) were considered statistically significant.
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